These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 7392547)

  • 1. Comparison of plasma levels and excretory routes between No. 189 and No. 407, potent thrombin inhibitors.
    Oda K; Ohtsu K; Tamao Y; Kikumoto R; Hijikata A; Kinjo K; Okamoto S
    Kobe J Med Sci; 1980 Mar; 26(1):11-31. PubMed ID: 7392547
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological characterization of a new highly effective synthetic thrombin inhibitor.
    Kaiser B; Hauptmann J; Weiss A; Markwardt F
    Biomed Biochim Acta; 1985; 44(7-8):1201-10. PubMed ID: 4084272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative studies on thrombin inhibitors in experimental microthrombosis.
    Markwardt F; Nowak G; Hoffmann J
    Thromb Haemost; 1983 Jun; 49(3):235-7. PubMed ID: 6603675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biliary excretion of synthetic benzamidine-type thrombin inhibitors in rabbits and rats.
    Hauptmann J; Kaiser B; Paintz M; Markwardt F
    Biomed Biochim Acta; 1987; 46(6):445-53. PubMed ID: 3675563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of a benzamidoxime derivative to the corresponding benzamidine in vivo and in vitro.
    Hauptmann J; Paintz M; Kaiser B; Richter M
    Pharmazie; 1988 Aug; 43(8):559-60. PubMed ID: 3237753
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of a potent thrombin inhibitor, No. 407, on platelet function in vitro and in vivo.
    Hara H; Tamao Y; Kikumoto R; Funahara Y; Hijikata A; Okamoto S
    Kobe J Med Sci; 1980 Mar; 26(1):47-60. PubMed ID: 7392549
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
    Lee K; Park CW; Jung WH; Park HD; Lee SH; Chung KH; Park SK; Kwon OH; Kang M; Park DH; Lee SK; Kim EE; Yoon SK; Kim A
    J Med Chem; 2003 Aug; 46(17):3612-22. PubMed ID: 12904065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SSR182289A, a novel, orally active thrombin inhibitor: in vitro profile and ex vivo anticoagulant activity.
    Berry CN; Lassalle G; Lunven C; Altenburger JM; Guilbert F; Lalé A; Hérault JP; Lecoffre C; Pfersdorff C; Herbert JM; O'Connor SE
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1189-98. PubMed ID: 12438543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proceedings: Animal experiments of a new synthetic thrombin-inhibitor, dansyl-arginine-methyl-piperidine amide.
    Hijikate A; Okamoto S; Ikezawa K; Kikimoto R; Tonomura S; Tamao Y
    Thromb Diath Haemorrh; 1975 Sep; 34(1):347-8. PubMed ID: 1188794
    [No Abstract]   [Full Text] [Related]  

  • 10. Proceedings: A series of extremely potent thrombin-inhibitors newly synthetized.
    Okamoto S; Hijikata A; Kikumoto R; Tonomura S; Tamao Y
    Thromb Diath Haemorrh; 1975 Sep; 34(1):364-5. PubMed ID: 1188831
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacological characterization of a new structural variant of 4-amidinophenylalanine amide-type synthetic thrombin inhibitor.
    Hauptmann J; Kaiser B; Paintz M; Markwardt F
    Pharmazie; 1989 Apr; 44(4):282-4. PubMed ID: 2772004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position.
    Feng DM; Gardell SJ; Lewis SD; Bock MG; Chen Z; Freidinger RM; Naylor-Olsen AM; Ramjit HG; Woltmann R; Baskin EP; Lynch JJ; Lucas R; Shafer JA; Dancheck KB; Chen IW; Mao SS; Krueger JA; Hare TR; Mulichak AM; Vacca JP
    J Med Chem; 1997 Nov; 40(23):3726-33. PubMed ID: 9371237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
    Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.
    Stürzebecher J; Prasa D; Hauptmann J; Vieweg H; Wikström P
    J Med Chem; 1997 Sep; 40(19):3091-9. PubMed ID: 9301673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo comparison of arginine- and benzamidine-derived highly potent synthetic thrombin inhibitors.
    Hauptmann J; Kaiser B
    Pharmazie; 1991 Jan; 46(1):57-8. PubMed ID: 1857734
    [No Abstract]   [Full Text] [Related]  

  • 16. Anticoagulant action of synthetic tight binding inhibitors of thrombin in vitro and in vivo.
    Hauptmann J; Kaiser B; Markwardt F
    Thromb Res; 1985 Sep; 39(6):771-5. PubMed ID: 4082110
    [No Abstract]   [Full Text] [Related]  

  • 17. Selective and dual action orally active inhibitors of thrombin and factor Xa.
    Young RJ; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Hubbard JA; Kelly HA; Pateman AJ; Patikis A; Senger S; Shah GP; Toomey JR; Watson NS; Zhou P
    Bioorg Med Chem Lett; 2007 May; 17(10):2927-30. PubMed ID: 17420122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic properties of SSR182289A, a new, orally active thrombin inhibitor.
    Lorrain J; Millet L; Lechaire I; Lochot S; Ferrari P; Visconte C; Sainte-Marie M; Lunven C; Berry CN; Schaeffer P; Herbert JM; O'Connor SE
    J Pharmacol Exp Ther; 2003 Feb; 304(2):567-74. PubMed ID: 12538808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological properties of 3-n-butylamino-4-phenoxy-5-sulfamylbenzoic acid (Bumetanide), a new potent diuretic.
    Ostergaard EH; Magnussen MP; Nielsen CK; Eilertsen E; Frey HH
    Arzneimittelforschung; 1972 Jan; 22(1):66-72. PubMed ID: 5067001
    [No Abstract]   [Full Text] [Related]  

  • 20. Exploration of potential prodrugs of RWJ-445167, an oxyguanidine-based dual inhibitor of thrombin and factor Xa.
    Maryanoff BE; McComsey DF; Costanzo MJ; Yabut SC; Lu T; Player MR; Giardino EC; Damiano BP
    Chem Biol Drug Des; 2006 Jul; 68(1):29-36. PubMed ID: 16923023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.